- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02047968
Wake and Light Therapy to In-patients With Major Depression: Efficacy, Predictors and Patient Experiences
Wake and Light Therapy to In-patients With Major Depression: A Randomized Controlled Trail, Efficacy, Predictors and Patient Experiences
Study Overview
Detailed Description
Background: About 150,000 Danes will constantly have symptoms of depression, and 20% of those are admitted to a psychiatric hospital at least once. When admitted, the patients are highly tormented and many have suicide thoughts. The treatment of depression in a ward consists of beginning or adjustment of antidepressive medication combined with for instance milieu therapy, psychotherapy and exercise offers. Full effect of medical treatment is only reached after 4-6 weeks, and no quicker effect is documented in the other treatment methods. Therefore, methods are needed which quickly, effectively and without large side effects can reduce the symptoms. Wake therapy is a treatment method which has appeared to stop or reduce depressive symptoms within hours, and several studies have demonstrated that up to 66% of the patients responded to wake therapy. The method consists in the patients staying awake for one night and the following day, in all 36 hours, which is followed by one night of sleep. Light therapy and stabilisation of circadian rhythm have been shown to maintain the effect of wake therapy.
Objective: To examine the efficacy of using wake and light therapy as a supplement to standard treatment of hospitalised patients with depression and to identify the characteristics of patients who accept and respond well to the treatment.
Methods: The project is carried out as a randomised controlled study and will include 74 patients with bipolar or unipolar depression. The patients are randomised to standard treatment or to the intervention, which besides standard treatment will consist of three times wake therapy in one week and 30 minutes daily light treatment in the entire nine week study period as well as ongoing guidance in good sleep hygiene. Raters for the Hamilton rating will be blinded to the treatment assignment.
Outcome: Primary outcome criteria will be the response rate in week two. Response is defined as a 50 % reduction or more compared to the baseline score in HAM-D 17. Secondary outcomes will be the remission rate in week two, the length of admission and the percentage of patients with response and remission in week nine.
Variables and Assessment: Severity of depression will be assessed by using the interview-based Hamilton Depression Rating scale, both the 17 item and the 6 item version. For patient-reported outcome measures the Major Depression Inventory (MDI) and the World Health Organisation (WHO)-5 wellbeing Index (WHO-5) will be used. Social and Occupational Functional Assessment Scale (GAF) and Bech-Rafaelsen mania scala (MAS) will also be recorded.
Data analysis: Data will be analysed in SPSS and presented descriptively in the two Groups to show whether the randomisation succeeded. A "intention to treat" analysis will be conducted, and on the basis of a requisite analysis a t-test, Mann-Whitney-Wilcoxon test or chi2-test will be used. The association between predictive factors and response to wake therapy will be described with prevalence proportions, ratios and will be analysed with a chi2-test. The level of statistical significance will be set at 5 %. The randomisation will be computer-generated, and the patients will be randomly allocated to the intervention group or the control group.
Sample size: The literature shows response rates at 41% after two weeks in the intervention group and 13 % in the control group. A power analysis based on these rates show that if α = 0,05 and β = 0,80, 37 patients should be included in each group, totally 74 patients.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Central Denmark Region
-
Risskov, Central Denmark Region, Denmark, 8240
- Mette Kragh
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A diagnosis of major depression according to DSM-IV
- A score on the Hamilton Depression Scale, 17 items version of at least 18
- Patient with major depression as part of a bipolar disorder should be in adequate mood stabilising therapy at entry to the study
- Age of 18 to 65
- Speak and understand Danish
Exclusion Criteria:
- Severe suicidal ideation (a score of 3 or above on the Hamilton Depression Scale, 17-items version)
- Anxiety psychic or somatic (a score of 3 or above on the Hamilton Depression Scale, 17-items version)
- personality disorder according to DSM-IV
- Drug or alcohol abuse
- Psychotic disorder
- Pregnancy
- Glaucoma
- Epilepsy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: treatment as usual
|
|
|
Experimental: wake therapy, light therapy and sleep time stabilisation
Wake therapy/sleep deprivation: Patients are awake for 36 hours three times in one week with a normal night of sleep between.
Light therapy for 30 minutes daily in the entire study period.
Sleep time stabilisation which involves psychoeducation regarding sleep hygiene and keeping the day-night cycle constant.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Response
Time Frame: Week two
|
Response is defined as a 50 % reduction or more compared to the baseline score in HAM-D 17.
|
Week two
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Remission
Time Frame: Week two
|
Remission will be defined as a score of <8 in HAM-D 17.
|
Week two
|
|
Length of admission
Time Frame: Week nine
|
Week nine
|
|
|
Percentage of patients with response
Time Frame: week nine
|
Response is defined as a 50 % reduction or more compared to the baseline score in HAM-D 17.
|
week nine
|
|
Percentage of patients with remission
Time Frame: week nine
|
Remission will be defined as a score of <8 in HAM-D 17.
|
week nine
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mette Kragh, RN, MSc, PhDstudent, Department of Affective Disorders Q
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VT12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depression
-
Johns Hopkins UniversityNot yet recruitingMajor Depression | Major Depression Moderate | Major Depression SevereUnited States
-
Technical University of MunichEnrolling by invitationMajor Depression Moderate | Major Depression SevereGermany
-
Stanford UniversityTerminatedMajor Depressive Disorder | Major Depressive Episode | Major Depressive Disorder, Recurrent | Major Depression Mild | Major Depression Moderate | Major Depression SevereUnited States
-
Hawler Medical UniversityCompleted
-
Centre Hospitalier Universitaire de BesançonH. Lundbeck A/SCompletedResistant Major DepressionFrance
-
Cybin IRL LimitedWorldwide Clinical TrialsRecruitingDepression | Major Depressive Disorder (MDD) | Depression - Major Depressive Disorder | Depression in Adults | Depression Disorders | Depression DisorderUnited States, United Kingdom, Germany, Greece, Australia, Poland, Ireland, Czechia
-
First Affiliated Hospital of Zhejiang UniversityCompleted
-
University of PittsburghCompletedPostpartum Major DepressionUnited States
-
Si TianmeiUnknownMajor Depression DisorderChina
-
The Hong Kong Polytechnic UniversityActive, not recruitingHealthy | Major Depression in RemissionChina
Clinical Trials on wake therapy
-
University of Massachusetts, AmherstUniversity of Maryland, College ParkRecruiting
-
KU LeuvenRecruitingParkinson Disease | AgingBelgium
-
University of Massachusetts, AmherstRecruiting
-
Brigham and Women's HospitalCompletedPhysiologyUnited States
-
Northwestern UniversityRecruitingSleep Apnea Obstructive (OSA)United States
-
University of PittsburghNational Institute on Drug Abuse (NIDA)Recruiting
-
Applied CognitionUniversity of Florida HealthCompleted
-
King's College LondonKings Health PartnersCompletedDepression | Depressive Disorder, Major | Depression, Unipolar | Depression ModerateUnited Kingdom
-
Lee Anne SiegmundRecruitingHeart FailureUnited States
-
Brigham and Women's HospitalCharite University, Berlin, Germany; Stanford UniversityTerminatedSleep Disorders, Intrinsic | Sleep Wake Disorders | Sleep Disorders, Circadian Rhythm | Advanced Sleep Phase Syndrome (ASPS) | Delayed Sleep Phase Syndrome | Shift-Work Sleep Disorder | Delayed Sleep Phase | Non-24 Hour Sleep-Wake Disorder | Advanced Sleep Phase Syndrome | Advanced Sleep Phase | Irregular... and other conditionsUnited States